RecruitingNCT06206681

Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors


Sponsor

Sun Yat-sen University

Enrollment

1,000 participants

Start Date

Nov 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to assess the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision in the treatment of eyelid tumors, including xanthelasma, pigmented nevi, keratoses, and so on.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates whether a type of CO2 laser treatment (called UltraPulse) is safe and effective for removing growths on the eyelids, such as fatty deposits (xanthelasma), moles, warts, and other benign lesions. **You may be eligible if...** - You have been clinically diagnosed with benign eyelid growths such as xanthelasma, pigmented moles, or keratoses - You have no history of light sensitivity, or bleeding/clotting disorders - You are willing to attend scheduled follow-up appointments **You may NOT be eligible if...** - You have an active infection near the treatment area - You have a history of abnormal scarring (keloids) - You are pregnant or breastfeeding - You have used blood-thinning medications recently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREUltra-pulsed Carbon Dioxide Laser

Excision of eyelid lesion


Locations(1)

Sun Yat-sen University

Guanzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06206681


Related Trials